source
- UniQure shares tumble as Huntington's gene therapy shows reduced benefit over timeUniQure announced new follow-up data from its experimental gene therapy for Huntington's disease, indicating the treatment's effect may diminish with longer observation. The additional year of dat…
- Roche drops anti-myostatin obesity drug after mid-stage trial shows limited weight lossRoche announced it will stop development of its anti-myostatin obesity candidate emugrobart after an interim analysis of the Phase 2 GYMINDA trial showed it is unlikely to produce meaningful weight…